Name: Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial
Brand: reuters.com
SKU: reuters-com-1604
Availability: OnlineOnly

critic

Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial

preview

By However, it is unclear whether elderly people, one of the populations most at risk from the virus, will be protected to the same degree as younger people with the J&amp;J vaccine.The trial in close to 1,000 healthy adults, which is backed by the U.S. government, began after the J&amp;J vaccine was found in July to offer strong protection in a single dose to monkeys.Based on the current results, J&amp;J on Wednesday kicked off a final 60,000-person trial, which could pave the way for an application for regulatory approval. The company said it expects results of that so-called Phase 3 trial by the end of the year or early next year.The results, released on the medical website medRxiv, have not been peer-reviewed. ()Researchers, including those from J&amp;J’s unit Janssen Pharmaceuticals, said 98% of participants with data available for the interim analysis had neutralizing antibodies, which defend cells from pathogens, 29 days after vaccination.However, immune response results were available from only a small number of people - 15 participants - over 65 years old, limiting the interpretation.In participants older than 65, the rate of adverse reactions such as fatigue and muscle aches was 36%, much lower than the 64% seen in younger participants, the results showed, suggesting the immune response in older people may not be as strong.The researchers said more details on safety and effectiveness will follow when the study is completed.For now, the results justify why more studies are needed in larger numbers to look for serious adverse effects, Dr. Barry Bloom, a professor at Harvard T.H. Chan School of Public Health who was not involved in the J&amp;J trial, told Reuters.“Overall, the vaccine is doing what you would expect it to do if you were to move it to Phase 3 trials,” Bloom said.Reporting by Vishwadha Chander and Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila, Nancy Lapid and Will DunhamOur Standards:

By However, it is unclear whether elderly people, one of the populations most at risk from the virus, will be protected to the same degree as younger people with the J&amp;J vaccine.The trial in close to 1,000 healthy adults, which is backed by the U.S. government, began after the J&amp;J vaccine was found in July to offer strong protection in a single dose to monkeys.Based on the current results, J&amp;J on Wednesday kicked off a final 60,000-person trial, which could pave the way for an application for regulatory approval. The company said it expects results of that so-called Phase 3...

public

Vishwadha Chander

Top and breaking news, pictures and videos from Reuters. For more breaking business news, follow @ReutersBiz.

reuters.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS